Professor, Department of Pharmaceutics; Affiliate Investigator, Fred Hutchinson Cancer Research Center
PhD in Pharmaceutical Chemistry, University of California-San Francisco; Bachelor of Science in Biochemistry, Peking University
- Mechanism of drug transport and disposition in the CNS
- Role of membrane transporters in drug elimination in the kidney
- Roles of membrane transporters in drug disposition and action
- PMAT as a novel drug target for brain disorders
- Transporter-mediated organ toxicity and adverse drug reaction
- Transporter-mediated drug-drug interactions
Dr. Wang's primary research interests are in the area of solute carrier (SLC) proteins that transport neurotransmitters, drugs and toxins across biological membranes. The central theme of Dr. Wang’s research has been focused on understanding the biology, physiology and pharmacology of SLC transporters and their clinical significance in drug disposition and action. Wang is noted for her research on plasma membrane monoamine transporter (PMAT or ENT4, SLC29A4), a novel neurotransmitter and organic cation transporter first discovered, cloned and characterized in her laboratory. Her work has shown that PMAT is a major low-affinity, high-capacity (uptake 2) transporter for monoamine neurotransmitters (e.g. 5HT, dopamine) in the central nervous system and may serve as a novel drug target for monoamine-related neuropsychiatric and neurodegenerative diseases.
Dr. Wang has served for national and international funding agencies, scientific journals and scholarly organizations. She has served on numerous special emphasis panels for National Institutes of Health (NIH) and is currently a member of the NIH Xenobiotic and Nutrient Disposition and Action study section.